传统、补充与整合医学干预COVID-19的随机对照试验:文献计量分析与研究设计综述
该文献计量分析检索六个数据库至2021年7月15日,纳入56篇TCIM-focused RCT,涉及553位作者,中国发文最多,其次为印度和美国。研究最常涉及的干预为中药汤剂(n=12)和中成药(n=16),多数试验样本量小至中等且为开放标签设计。
要点
- 中国是TCIM干预COVID-19的RCT发文最多的国家,其次为印度和美国。
- 最常研究的TCIM干预为中药汤剂(n=12)和中成药(n=16)。
- 多数试验样本量小至中等,且为开放标签设计,与标准药物联合应用。
核心结论
- 该文献计量分析展示了TCIM用于COVID-19研究的趋势和特征。
- 尽管大流行研究仍存在许多空白和局限,TCIM-focused RCT的发表预计将持续增加。
研究设计与样本
- 于2021年7月15日检索六个数据库,纳入所有涉及至少一种TCIM用于COVID-19治疗和/或管理的RCT。
- 共纳入56篇文章,由553位独特作者撰写,包括28篇英文文章、19篇中文文章带英文摘要、9篇中文文章无英文摘要。
- 提取并分析试验数量、国家、发表期刊、研究焦点、研究设计和样本量等数据。
主要发现
- 中国是TCIM相关RCT发文的主导国家,其次是印度和美国。
- 纳入文章发表在24种英文期刊和22种中文期刊上,影响因子范围为0.220至56.272。
- 最常研究的TCIM模式包括中药汤剂(n=12)和中成药(n=16)。
- TCIM干预在试验中与标准药物整合,大多数试验样本量小至中等且为开放标签设计。
关键数值与推荐
- 纳入标准:RCT提及至少一种TCIM用于COVID-19的治疗和/或管理。
- 共纳入56篇RCT文章,涉及553位独特作者。
- 中药汤剂研究n=12,中成药研究n=16。
- 发表期刊影响因子范围0.220至56.272。
临床怎么用
- 临床参考时需注意多数TCIM干预COVID-19的RCT样本量小至中等且为开放标签设计。
- 中药汤剂和中成药是研究最集中的TCIM干预类型,但证据强度受研究设计限制。
局限性
- 多数试验样本量小至中等且为开放标签设计。
- 大流行研究仍存在许多研究空白和局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To date, the coronavirus disease 2019 (COVID-19) pandemic remains ongoing and continues to affect millions of people worldwide. In the effort of fighting this pandemic, there has been an increasing interest in the potential of traditional, complementary, and integrative medicines (TCIMs) in engaging COVID-19. This study presents a bibliometric analysis of the research trends of TCIMs for COVID-19. METHODS: Six databases were searched on July 15, 2021, to retrieve all the citations on TCIM-focused randomized controlled trials (RCTs) available on COVID-19. Only RCTs that mentioned at least one TCIMs for the treatment and/or management or COVID-19 were eligible. Data such as number and countries of trials conducted, publication journal, research focus, study design, and sample size were extracted for analysis. RESULTS: The resulting 56 articles were authored by 553 unique authors, and included 28 English articles, 19 Chinese articles with English abstracts, and 9 Chinese articles without English abstract. Analyses had shown that China was the dominant country with TCIM related RCT publications, followed by India and the United States. The included articles were published across 24 English journals and 22 Chinese journals with a wide range of impact factors from 0.220 to 56.272. The most commonly studied TCIM modalities included Chinese herbal decoction (n=12) and Chinese patent medicine (n=16). In terms of study designs, TCIM interventions were integrated with standard medicine across the trials with most trials having a small to medium sample size and open-labeled. CONCLUSION: This bibliometric analysis of RCTs demonstrated the research trends and characteristics of TCIM utilized in COVID-19 research. Although there are still many research gaps and limitations for pandemic research, the publication of TCIM-focused RCTs is anticipated to show a continuously increasing trend.
引用
- Ang L, Song E, Lee MS, et al. Randomized controlled trials of traditional, complementary, and integrative medicine-based interventions for coronavirus disease 2019 (COVID-19): A bibliometric analysis and review of study designs. Integr Med Res. 2021. PMID: 34580628. doi:10.1016/j.imr.2021.100777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。